1
Clinical Trials associated with Influenza A virus H7N9 vaccine nanopatch (Vaxxas)Phase I Clinical Study to Evaluate the Safety and Tolerability of a Monovalent Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) in Healthy Adults Aged 18 to 50 Years
Study SP-1219-007 is a multi-centre, randomised, study designed to access the safety and tolerability of two doses of monovalent Influenza A (H7N9) vaccine delivered intradermally by a microarray patch delivery system in healthy adults aged 18 to 50 years.
100 Clinical Results associated with Influenza A virus H7N9 vaccine nanopatch (Vaxxas)
100 Translational Medicine associated with Influenza A virus H7N9 vaccine nanopatch (Vaxxas)
100 Patents (Medical) associated with Influenza A virus H7N9 vaccine nanopatch (Vaxxas)
100 Deals associated with Influenza A virus H7N9 vaccine nanopatch (Vaxxas)